Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference
- Presentation underscores potential of several high-impact launches across Oncology and Inflammation & Autoimmunity to drive sustainable long-term growth
- Company announces new positive topline results from Phase 2 trial evaluating ruxolitinib cream (Opzelura®) in adults with hidradenitis suppurativa (HS)
- Overview of early pipeline, including preliminary results from Phase 1 study of INCB123667 (CDK2i), will also be presented
“As we enter 2024, we see great promise in our portfolio and its potential to drive long-term growth fueled by our strong R&D engine and broad commercial footprint across Oncology and Inflammation & Autoimmunity,” said
Additionally, the Company will highlight progress across its Oncology pipeline and the research it is advancing in areas of high potential, including promising early clinical efficacy data for INCB123667, a potent and selective inhibitor of CDK2, demonstrating its potential use as monotherapy or combination therapy for late-stage cancers. In a Phase 1 study of INCB123667, early clinical activity was observed with several patients with amplified/overexpression of CCNE1, a cell cycle regulator and potential predictive biomarker, achieving partial response (PR). Tumor shrinkage was observed across multiple tumor types, including CCNE+ patients with ovarian cancer. The safety profile of for INCB123667 aligns with the mechanism of action.
- Expanding leadership in myeloproliferative neoplasms (MPNs) and graft-versus-host disease (GVHD) with a pipeline including axatilimab, mCALR and V617F that has disease-modifying potential for patients with graft-versus-host disease and the more than 200,000 patients with myelofibrosis, polycythemia vera and essential thrombocythemia.
- Its emerging dermatology franchise, and the intent to maximize the potential of ruxolitinib cream (Opzelura) and expand povorcitinib into multiple indications with high unmet need.
The Company intends to provide additional financial guidance and updates on key clinical programs during its 2023 fourth quarter and year-end earnings conference call.
A global biopharmaceutical company on a mission to Solve On.,
About Opzelura® (ruxolitinib) Cream 1.5%
Opzelura, a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, is approved by the
Opzelura and the Opzelura logo are registered trademark of
Incyte Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release contain predictions, estimates and other forward-looking statements, including without limitation statements regarding: the opportunities for sustainable growth presented by Incyte’s pipeline and products, including multiple programs across oncology and inflammation & autoimmunity, as well as dermatology; expectations regarding Incyte’s R&D and commercial execution; expectations regarding near/mid-term product launches; the potential for sustaining and expanding Incyte’s leadership in MPNs and GVHD and the potential for such innovation to address the needs of more than 200,000 patients; the potential for CDK2i in late stage cancers, including ovarian cancer; opportunities to maximize the potential of Opzelura and Incyte’s expectations for Opzelura in atopic dermatitis, vitiligo and HS; the development of Incyte’s dermatology portfolio beyond Opzelura, including povorcitinib in multiple indications; and expectations regarding clinical trials and results and the timing for same.
These forward-looking statements are based on our current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; the effects of the COVID-19 pandemic and measures to address the pandemic on our clinical trials, supply chain and other third-party providers, sales and marketing efforts, and business, development, and discovery operations, as well as on regulatory agencies such as the FDA; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; determinations made by the FDA and regulatory agencies outside of